Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 11/20 | 0.49 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | FLT4 | P35916 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.38 |
| ▸ | TEK | Q02763 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
| ▸ | PRKACA | P17612 | 1/20 | 0.35 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15181504 | 0.89 | DGAT1 (0.49) | DGAT1GRM5PRKACARPS6KB1 | |
| SCHEMBL84579 | 0.79 | DGAT1 (0.39) | DGAT1FYNPIK3CAADORA1 | |
| SCHEMBL16661146 | 0.78 | DGAT1 (0.66) | DGAT1GRM5PRKACARPS6KB1 | |
| SCHEMBL67976 | 0.77 | DGAT1 (0.50) | DGAT1GRM5 | |
| SCHEMBL24229514 | 0.72 | DGAT1 (0.47) | DGAT1PRKACARPS6KB1 | |
| SCHEMBL19065558 | 0.71 | DGAT1 (0.46) | DGAT1GRM5 | |
| SCHEMBL84164 | 0.71 | DGAT1 (0.56) | DGAT1 | |
| SCHEMBL67109 | 0.70 | TNIK (0.43) | DGAT1GRM5FYNPIK3CA | |
| SCHEMBL19065700 | 0.70 | DGAT1 (0.45) | DGAT1 | |
| SCHEMBL31181648 | 0.70 | DGAT1 (0.45) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | DGAT1 3367/4885GRM5 3996/4885FYN 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.